Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5009
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides.

    To find out more about Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
4SC
7TM Pharma
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Adherex
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allist Pharmaceuticals
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Bavarian Nordic
Baxter International
Bayer
Benitec
Berkeley Lab
Betapharma
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocompatibles
Biogen Idec
Biokine Therapeutics
Bionovo
BioNumerik
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
Camurus
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chiasma
Choongwae
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinical Data
Clinuvel
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cosmo Pharmaceuticals
CuraGen
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dongkook Pharm
Dyax
Dynavax Technologies
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
FasTrack Pharmaceuticals
Formula Pharmaceuticals
Galapagos
Galena Biopharma
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
GPC Biotech
Gradalis
Green Cross
Gryphon Therapeutics
Hanmi
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
IkerChem
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
Immunomedics
Immunotope
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirax
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Labopharm
Lee’s Pharmaceutical
Leo
Lexicon Pharmaceuticals
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Mologen
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Nerviano Medical Sciences
Neurobiological Technologies
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
NovaLead
Novartis
Novogen
NPS Pharmaceuticals
Nycomed Pharma
Oncalis
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
Pathway Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
POZEN
Pro-Pharmaceuticals
Proacta
Progenics Pharmaceuticals
Protagonist
Protherics
Provid
Q Chip
QLT
Quantum Pharmaceuticals
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Rexahn
Rigel
Samtheo Biopharma
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SciClone Pharmaceuticals
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
SRI International
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TauTaTis
Taxolog
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
UCB
Unigene
United Biomedical
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroMed
Wyeth
Xcovery
Xencor
Xerion
Xigen
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AC-480
AE-37
AEZS-108
AF-802
afamelanotide
afatinib
aflibercept
alvocidib
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
AR-42
ARQ-197
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
brivanib alaninate
Cabozantinib
CAL-101
capecitabine
catumaxomab
CBP-501
CC-223
cediranib
cetuximab
corticorelin acetate
crizotinib
dacomitinib
danusertib
dasatinib
deslorelin
dinaciclib
dovitinib lactate
doxifluridine
E-75
emepepimut-S
endoxifen
ENMD-2076
enzastaurin hydrochloride
EP-100
erlotinib
everolimus
foretinib
fostamatinib disodium
FPI-01
gefitinib
goserelin
GSK-2118436
GV-1001
GX-301
Her-2/Neu peptides
histrelin
IC-83
icrucumab
idronoxil
imatinib mesilate
imMucin
INCB-028060
INSM-18
interferon gamma
IPP-204106
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
JI-101
kahalalide F
KD032
KX2-391
lanreotide
lapatinib ditosylate
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
linsitinib
LY-2090314
masitinib
MDX-1379
MGCD-265
MGN-1703
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
NAFB001
neratinib
netupitant
nilotinib
NPB-001-056
octreotide
octreotide, LAR
ON-01910
onartuzumab
OSI-027
OTS-102
ozarelix
P276-00
panitumumab
pasireotide
pasireotide LAR
pazopanib hydrochloride
PD-0332991
pegdinetanib
perifosine
PHA-848125AC
plitidepsin
polyclonal antibody stimulator
ponatinib
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
raltitrexed
ramucirumab
regorafenib
ridaforolimus
rilotumumab
rindopepimut
romurtide
ruxolitinib
RX-0201-N
SCH-900776
seliciclib
sirolimus
sorafenib tosylate
sotatercept
ß-lapachone
SU-6668
sunitinib malate
Survivac
talmapimod
tandutinib
tegafur + uracil
tegafur + uracil + leucovorin
telatinib
temsirolimus
terameprocol
thymalfasin
tivozanib
TM-30339
triciribine phosphate
TS-1
vandetanib
vapreotide, immediate-release
varlitinib
vemurafenib
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-281
XL-413
XL-647
XL-765

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides.
    To find out more about Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Melanoma. Learn More

Other selected research from the 'Oncology' category:


The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More


Triple Analysis: Prostate Cancer, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More